This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Vidofludimus
- DrugBank Accession Number
- DB15446
- Background
Vidofludimus is under investigation in clinical trial NCT03722576 (Vidofludimus Calcium for Primary Sclerosing Cholangitis).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Vidofludimus (DB15446)
- Weight
- Average: 355.365
Monoisotopic: 355.121986227 - Chemical Formula
- C20H18FNO4
- Synonyms
- Vidofludimus
- External IDs
- IMU-838
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Vidofludimus Calcium FW5VY7926X 1354012-90-0 KWSJBFAXOPFZSO-UHFFFAOYSA-L
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8Y1PJ3VG81
- CAS number
- 717824-30-1
- InChI Key
- XPRDUGXOWVXZLL-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
- IUPAC Name
- 2-({3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid
- SMILES
- COC1=CC(=CC=C1)C1=CC=C(NC(=O)C2=C(CCC2)C(O)=O)C(F)=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 7995757
- BindingDB
- 16111
- ChEMBL
- CHEMBL197194
- ZINC
- ZINC000014960644
- PDBe Ligand
- D5H
- PDB Entries
- 5y1j
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Multiple Sclerosis 1 3 Recruiting Treatment Relapsing Remitting Multiple Sclerosis (RRMS) 1 2 Active Not Recruiting Treatment Relapsing Remitting Multiple Sclerosis (RRMS) 1 2 Active Not Recruiting Treatment Ulcerative Colitis 1 2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1 2 Completed Treatment Primary Sclerosing Cholangitis (PSC) 1 2 Recruiting Treatment Multiple Sclerosis 1 2, 3 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00413 mg/mL ALOGPS logP 3.36 ALOGPS logP 3.8 Chemaxon logS -4.9 ALOGPS pKa (Strongest Acidic) 3.07 Chemaxon pKa (Strongest Basic) -1.4 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 75.63 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 96.21 m3·mol-1 Chemaxon Polarizability 35.31 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 15:32 / Updated at February 21, 2021 18:55